Abstract:Objective To analyze the clinical effect of Bisoprolol combined with Irbesartan on patients with chronic heart failure.Methods A total of 88 patients with chronic heart failure admitted to our hospital from July 2018 to July 2019 were selected as research objects.According to the single or even number of hospital beds,they were divided into treatment group (44 cases) and control group (44 cases).The control group was treated with Irbesartan.The treatment group was treated with Bisoprolol and Irbesartan.The cardiac function index,blood pressure,serum B-type brain natriuretic peptide (BNP) and high sensitivity C-reactive protein (hs-CRP) levels of the two groups were compared.Results The left ventricular ejection fraction (LVEF) level in the treatment group was higher than that in the control group,with statistical significance (P<0.05),while the left ventricular end diastolic diameter (LVEDD) and left ventricular end systolic diameter (LVESD) levels in the treatment group were lower than those in the control group,with statistical significances (P<0.05).The levels of BNP and hs-CRP in the treatment group were lower than those in the control group after treatment,and the differences were statistically significant (P<0.05).The systolic blood pressure (SBP),diastolic blood pressure (DBP) and pulse pressure difference after treatment in the treatment group were lower than those in the control group,with statistically significant differences (P<0.05).The total effective rate of the treatment group was higher than that of the control group,with statistically significant difference (P<0.05).Conclusion The combination of Bisoprolol and Irbesartan has definite effect on the treatment of chronic heart failure,which can effectively improve the cardiac function index of patients,regulate the blood pressure level of patients,optimize the serum BNP and hs-CRP levels of patients,and has higher application value in clinical practice.
黄小强; 胡亮明. 比索洛尔联合厄贝沙坦治疗慢性心力衰竭患者的临床效果[J]. 中国当代医药, 2020, 27(14): 65-67转71.
HUANG Xiao-qiang; HU Liang-ming. Clinical effect of Bisoprolol combined with Irbesartan in the treatment of patients with chronic heart failure. 中国当代医药, 2020, 27(14): 65-67转71.